
Recognizing the leading role China will take globally in the future of life sciences, trade group AusBiotech recently presented the second Australia China Life Science Summit in Sydney and now continues to “pave the way” for Australian companies interested in opportunities in and with China.
The 2014 Summit focused on the issues and challenges of doing business in China and how to navigate the ever-changing, rapidly-developing and complex China market to build mutually-fruitful partnerships. Over two days, delegates gained expert insights, heard case studies and shared knowledge and experiences with other companies that are planning to or have already created linkages with China. There were a number of key outcomes from the event, which include:
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze